Edition:
United Kingdom

Catalyst Pharmaceuticals Inc (CPRX.OQ)

CPRX.OQ on NASDAQ Stock Exchange Capital Market

3.31USD
15 Oct 2018
Change (% chg)

-- (--)
Prev Close
$3.31
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
142,294
52-wk High
$4.51
52-wk Low
$2.20

Chart for

About

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's... (more)

Overall

Beta: 1.63
Market Cap(Mil.): $234.22
Shares Outstanding(Mil.): 84.55
Dividend: --
Yield (%): --

Financials

  CPRX.OQ Industry Sector
P/E (TTM): -- 85.91 32.75
EPS (TTM): -0.20 -- --
ROI: -42.00 1.70 14.60
ROE: -42.26 3.17 16.33

BRIEF-Catalyst Pharmaceuticals Reports Q1 GAAP Loss Per Share $0.06

* CATALYST PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

09 May 2018

BRIEF-Catalyst Pharmaceuticals Announces Enrollment Of First Patient In Phase 3 Trial Of Firdapse In Musk Antibody Positive Myasthenia Gravis

* CATALYST PHARMACEUTICALS ANNOUNCES ENROLLMENT OF FIRST PATIENT IN PHASE 3 TRIAL OF FIRDAPSE® IN MUSK ANTIBODY POSITIVE MYASTHENIA GRAVIS Source text for Eikon: Further company coverage:

19 Apr 2018

Competitors

Earnings vs. Estimates